[Sulfonylureas in today's blood glucose lowering therapy. New data on advantages and potential barriers of an "old" antidiabetic group].

Abstract

Sulfonylurea compounds have been basic elements of antidiabetic treatment in type 2 diabetes for a long time. However, with the introduction of incretin type insulin secretagogues it is often arises, whether is still there a place for sulfonylureas in the today's therapy. To answer this question the author overviews general pharmaceutical characteristics of the sulfonylurea compounds as well as individual particularities of the second generation derivatives used at present in Hungary. The author details also the most important differences between incretin type drugs - first of all dipeptidyl peptidase-4 inhibitors - and sulfonylureas. On the basis of available data it can be concluded in accordance with the latest international guidelines, that sulfonylureas have still role in the blood glucose lowering therapy of type 2 diabetes, though they became somewhat pushed back among insulin secretagogue type drugs. If a sulfonylurea compound is the drug of choice, it is important to select the appropriate molecule (in case of normal renal function gliclazide or glimepiride). It is also important to re-educate the patient, as well as to apply the minimal dose providing the desired glycaemic effect.

• Authors: Gábor Winkler
• Journal: Orvosi hetilap (Orv Hetil) Vol. 156 Issue 13 Pg. 511-5 (Mar 29 2015) ISSN: 0030-6002 [Print] Hungary
• Vernacular Title: Szulfanilureák napjaink vércukorcsökkentő kezelésében. Újabb adatok egy régi gyógyszercsoport előnyeiről és korlátairól.
• PMID: 25796278 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Blood Glucose
• Dipeptidyl-Peptidase IV Inhibitors
• Hypoglycemic Agents
• Incretins
• Insulin
• Sulfonylurea Compounds
• glimepiride
• Gliclazide

Topics

• Blood Glucose (drug effects, metabolism)
• Diabetes Mellitus, Type 2 (drug therapy)
• Dipeptidyl-Peptidase IV Inhibitors (therapeutic use)
• Gliclazide (therapeutic use)
• Humans
• Hungary
• Hypoglycemic Agents (therapeutic use)
• Incretins (therapeutic use)
• Insulin (therapeutic use)
• Sulfonylurea Compounds (therapeutic use)